Gain-of-function p53R172H mutation drives accumulation of neutrophils in pancreatic tumors, promoting resistance to immunotherapy
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Tumor genotype can influence the immune microenvironment, which plays a critical role in cancer development and therapy resistance. However, the immune effects of gain-of-function Trp53 mutations have not been defined in pancreatic cancer. We compare the immune profiles generated by Kras G12D -mutated mouse pancreatic ductal epithelial cells (PDECs) engineered genetically to express the Trp53 R172H mutation with their p53 wild-type control. Kras G12D/+ ; Trp53 R172H/+ tumors have a distinct immune profile characterized by an influx of CD11b + Ly6G + neutrophils and concomitant decreases in CD3 + T cells, CD8 + T cells, and CD4 + T helper 1 cells. Knockdown of CXCL2, a neutrophil chemokine, in the tumor epithelial compartment of CRISPR Kras G12D/+; Trp53 R172H/+ PDEC tumors reverses the neutrophil phenotype. Neutrophil depletion of mice bearing CRISPR Kras G12D/+ ; Trp53 R172H/+ tumors augments sensitivity to combined CD40 immunotherapy and chemotherapy. These data link Trp53 R172H to the presence of intratumoral neutrophils in pancreatic cancer and suggest that tumor genotypes could inform selection of affected individuals for immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved vectors and genome-wide libraries for CRISPR screening
Sanjana, N. E., Shalem, O., & Zhang, F. (2014) · Nature Methods · doi:10.1038/nmeth.3047 · Cited by 5,239
Genomic analyses identify molecular subtypes of pancreatic cancer
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621 · cited 3×
“In particular, the squamous subtype is correlated with TP53 mutations and has been observed to be enriched for a distinct immune cell-specific gene expression signature (Bailey et al., 2016).”
BackgroundCoordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544 · cited 1×
“In contrast, N2 neutrophils can promote tumor cell proliferation by inhibiting T cell activation through release of reactive oxygen species and arginase 1 and also facilitate metastasis by assisting with formation of a pre-metastatic niche (Coffelt et al., 2016; Gabrilovich et al., 2012; Park et al., 2016).”
BackgroundMelanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830 · cited 2×
“…A uthor M anuscript Different tumor genetic backgrounds can profoundly influence the composition of the immune microenvironment, as demonstrated in melanoma, breast, and prostate cancers, through distinct cellular mechanisms (Bezzi et al., 2018; Spranger et al., 2015; Wellenstein et al., 2019).”
BackgroundMarabelle, A., Fakih, M., Lopez, J., Shah, M., Shapira-Frommer, R., Nakagawa, K., Chung, H. C., Kindler, H. L., Lopez-Martin, J. A., Miller, W. H., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30445-9 · Cited by 2,552 · cited 1×
“Although tumor genotype is not currently utilized for selecting individuals for immunotherapy, with the exception of those with high mutational burden being considered for treatment with PD1 therapy (Marabelle et al., 2020), our study adds to the mounting evidence that suggests that affected individuals may be stratif…”
BackgroundIntegrated genomic characterization of pancreatic ductal adenocarcinoma
Raphael, B. J., Hruban, R. H., Aguirre, A. J., Moffitt, R. A., Yeh, J. J., Stewart, C., Robertson, A. G., Cherniack, A. D., Gupta, M., Getz, G., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.07.007 · Cited by 2,019 · cited 3×
“TP53 is mutated in up to 70% of PDACs, second in mutation frequency only to KRAS (Raphael et al., 2017).”
BackgroundNeutrophils in cancer: Neutral no more
Coffelt, S. B., Wellenstein, M. D., & de Visser, K. E. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.52 · Cited by 1,830 · cited 2×
“…N2 neutrophils can promote tumor cell proliferation by inhibiting T cell activation through release of reactive oxygen species and arginase 1 and also facilitate metastasis by assisting with formation of a pre-metastatic niche (Coffelt et al., 2016; Gabrilovich et al., 2012; Park et al., 2016).”
BackgroundWhole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets
Witkiewicz, A. K., McMillan, E. A., Balaji, U., Baek, G., Lin, W.-C., Mansour, J., Mollaee, M., Wagner, K.-U., Koduru, P., Yopp, A., et al. (2015) · Nature Communications · doi:10.1038/ncomms7744 · Cited by 1,115
Dynamics of the immune reaction to pancreatic cancer from inception to invasion
Clark, C. E., Hingorani, S. R., Mick, R., Combs, C., Tuveson, D. A., & Vonderheide, R. H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0175 · Cited by 990 · cited 1×
“Although changes to the immune microenvironment over time have been described during development of pancreatic cancer, how distinct immune cell populations correlate to specific tumor genotypes has not been determined (Clark et al., 2007).”
BackgroundCancer cells induce metastasis-supporting neutrophil extracellular DNA traps
Park, J., Wysocki, R. W., Amoozgar, Z., Maiorino, L., Fein, M. R., Jorns, J., Schott, A. F., Kinugasa-Katayama, Y., Lee, Y., Won, N. H., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aag1711 · Cited by 984
Bayne, L. J., Beatty, G. L., Jhala, N., Clark, C. E., Rhim, A. D., Stanger, B. Z., & Vonderheide, R. H. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.04.025 · Cited by 947 · cited 2×
“Several labs have demonstrated that KRASG12D mutations in tumor cells remodel the pancreatic immune microenvironment by recruiting immunosuppressive MDSCs and regulatory T cells (Bayne et al., 2012; Mathew et al., 2014; Pylayeva-Gupta et al., 2012; Zhang et al., 2017), but the effects of additional mutations have not…”
BackgroundOncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia
Pylayeva-Gupta, Y., Lee, K. E., Hajdu, C. H., Miller, G., & Bar-Sagi, D. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.04.024 · Cited by 721 · cited 4×
“Several labs have demonstrated that KRASG12D mutations in tumor cells remodel the pancreatic immune microenvironment by recruiting immunosuppressive MDSCs and regulatory T cells (Bayne et al., 2012; Mathew et al., 2014; Pylayeva-Gupta et al., 2012; Zhang et al., 2017), but the effects of additional mutations have not…”
BackgroundMethodInfluentialSelf-citationFKBP51 Affects Cancer Cell Response to Chemotherapy by Negatively Regulating Akt
Pei, H., Li, L., Fridley, B. L., Jenkins, G. D., Kalari, K. R., Lingle, W., Petersen, G., Lou, Z., & Wang, L. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.07.016 · Cited by 709
Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer
Morton, J. P., Timpson, P., Karim, S. A., Ridgway, R. A., Athineos, D., Doyle, B., Jamieson, N. B., Oien, K. A., Lowy, A. M., Brunton, V. G., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908428107 · Cited by 657
Myc Cooperates with Ras by Programming Inflammation and Immune Suppression
Kortlever, R. M., Sodir, N. M., Wilson, C. H., Burkhart, D. L., Pellegrinet, L., Brown Swigart, L., Littlewood, T. D., & Evan, G. I. (2017) · Cell · doi:10.1016/j.cell.2017.11.013 · Cited by 553
CD40 agonist antibodies in cancer immunotherapy
Vonderheide, R. H. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-062518-045435 · Cited by 544 · cited 1×
“…agonist antibody APX005M and chemotherapy (with or without nivolumab PD1 therapy) showed an encouraging overall response rate of 54% in a phase Ib trial of individuals with metastatic pancreatic cancer and is currently under evaluation in an ongoing randomized phase II study (Vonderheide, 2020).”
BackgroundLoss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis
Wellenstein, M. D., Coffelt, S. B., Duits, D. E. M., van Miltenburg, M. H., Slagter, M., de Rink, I., Henneman, L., Kas, S. M., Prekovic, S., Hau, C.-S., et al. (2019) · Nature · doi:10.1038/s41586-019-1450-6 · Cited by 500
Mutant p53 Drives Pancreatic Cancer Metastasis through Cell-Autonomous PDGF Receptor β Signaling
Weissmueller, S., Manchado, E., Saborowski, M., Morris, J. P., Wagenblast, E., Davis, C. A., Moon, S.-H., Pfister, N. T., Tschaharganeh, D. F., Kitzing, T., et al. (2014) · Cell · doi:10.1016/j.cell.2014.01.066 · Cited by 466 · cited 2×
“Neutrophil presence (Chao et al., 2016; Steele et al., 2016) and Trp53R172H gain-of-function mutation in tumor cells (Morton et al., 2010; Weissmueller et al., 2014) have been implicated independently in promoting metastasis in mouse models of PDAC.”
BackgroundDi Agostino, S., Strano, S., Emiliozzi, V., Zerbini, V., Mottolese, M., Sacchi, A., Blandino, G., & Piaggio, G. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.013 · Cited by 418
Inhibition of CXCR2 profoundly suppresses inflammation-driven and spontaneous tumorigenesis
Jamieson, T., Clarke, M., Steele, C. W., Samuel, M. S., Neumann, J., Jung, A., Huels, D., Olson, M. F., Das, S., Nibbs, R. J. B., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61067 · Cited by 391 · cited 1×
“The anti-Ly6G antibody 1A8 is an established means for successfully depleting Ly6G+ cells in vivo (Boivin et al., 2020; Jamieson et al., 2012; Steele et al., 2016), and we confirmed the efficiency of intratumoral neutrophil depletion in our mouse model Siolas et al.”
BackgroundCD40 stimulation obviates innate sensors and drives T cell immunity in cancer
Byrne, K. T., & Vonderheide, R. H. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.05.058 · Cited by 282 · cited 2×
“Treatment with a CD40 antibody activates antigen-presenting cells (APCs) that can elicit an immune response from T cells using tumor antigens released by chemotherapy-mediated cell destruction (Byrne and Vonderheide, 2016).”
BackgroundMethod
Cited by
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
de Visser, K. E., & Joyce, J. A. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.016 · Cited by 4,059
Therapeutic targeting of tumour myeloid cells
Barry, S. T., Gabrilovich, D. I., Sansom, O. J., Campbell, A. D., & Morton, J. P. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00546-2 · Cited by 305
Mechanisms driving the immunoregulatory function of cancer cells
van Weverwijk, A., & de Visser, K. E. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00544-4 · Cited by 272
Mutant p53: it’s not all one and the same
Kennedy, M. C., & Lowe, S. W. (2022) · Cell Death & Differentiation · doi:10.1038/s41418-022-00989-y · Cited by 198
Metadata
- Authors
- Siolas, D., Vucic, E., Kurz, E., Hajdu, C., & Bar-Sagi, D.
- Venue
- Cell Reports
- Publisher
- Elsevier BV
- Published
- 2021-08
- Volume
- 36
- Issue
- 8
- Pages
- 109578
- ISSN
- 2211-1247 (ISSN-L)
- OpenAlex
- W3195220415
- Cited by
- 80
- References
- 21
- FWCI
- 4.09
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.